These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10524570)

  • 1. Degradation of extracellular matrix by metastatic follicular thyroid carcinoma cell lines: role of the plasmin activation system.
    Smit JW; van der Pluijm G; Romijn HA; Löwik CW; Morreau H; Goslings BM
    Thyroid; 1999 Sep; 9(9):913-9. PubMed ID: 10524570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines.
    Havekes B; Schröder van der Elst JP; van der Pluijm G; Goslings BM; Romijn JA; Smit JW
    J Endocrinol; 2000 Nov; 167(2):229-38. PubMed ID: 11054636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of IL-1alpha on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in osteoblastic ROS 17/2.8 cells.
    Fujisaki K; Tanabe N; Suzuki N; Mitsui N; Oka H; Ito K; Maeno M
    Life Sci; 2006 Mar; 78(17):1975-82. PubMed ID: 16313928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expressions of urokinase-type plasminogen activator, its receptor and plasminogen activator inhibitor-1 in gastric cancer cells and effects of Helicobacter pylori.
    Iwamoto J; Mizokami Y; Takahashi K; Nakajima K; Ohtsubo T; Miura S; Narasaka T; Takeyama H; Omata T; Shimokobe K; Ito M; Takehara H; Matsuoka T
    Scand J Gastroenterol; 2005 Jul; 40(7):783-93. PubMed ID: 16109653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines.
    Baldini E; Toller M; Graziano FM; Russo FP; Pepe M; Biordi L; Marchioni E; Curcio F; Ulisse S; Ambesi-Impiombato FS; D'Armiento M
    Thyroid; 2004 Nov; 14(11):881-8. PubMed ID: 15671765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intrafollicular indomethacin injection on gonadotropin surge-induced expression of select extracellular matrix degrading enzymes and their inhibitors in bovine preovulatory follicles.
    Li Q; Jimenez-Krassel F; Kobayashi Y; Ireland JJ; Smith GW
    Reproduction; 2006 Mar; 131(3):533-43. PubMed ID: 16514196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
    Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
    Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective processing of the transforming growth factor-beta1 in azoxymethane-induced mouse colon tumors.
    Guda K; Claffey KP; Dong M; Nambiar PR; Rosenberg DW
    Mol Carcinog; 2003 May; 37(1):51-9. PubMed ID: 12720300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
    Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of integrins in the attachment of metastatic follicular thyroid carcinoma cell lines to bone.
    Smit JW; van der Pluijm G; Vloedgraven HJ; Löwik CW; Goslings BM
    Thyroid; 1998 Jan; 8(1):29-36. PubMed ID: 9492150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of CLAUDIN-1 on follicular thyroid carcinoma aggressiveness.
    Zwanziger D; Badziong J; Ting S; Moeller LC; Schmid KW; Siebolts U; Wickenhauser C; Dralle H; Fuehrer D
    Endocr Relat Cancer; 2015 Oct; 22(5):819-30. PubMed ID: 26219679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: correlation with metastatic behavior in vivo.
    Quax PH; de Bart AC; Schalken JA; Verheijen JH
    Prostate; 1997 Aug; 32(3):196-204. PubMed ID: 9254899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential.
    Nishikawa A; Iwasaki M; Akutagawa N; Manase K; Yamashita S; Endo T; Kudo R
    Gynecol Oncol; 2000 Nov; 79(2):256-63. PubMed ID: 11063654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 regulates production of plasminogen activator isoenzymes, urokinase receptor, and plasminogen activator inhibitor-1 in primary cultures of rat calvarial osteoblasts.
    Allan EH; Martin TJ
    J Cell Physiol; 1995 Dec; 165(3):521-9. PubMed ID: 7593231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor-beta1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system.
    Ramont L; Pasco S; Hornebeck W; Maquart FX; Monboisse JC
    Exp Cell Res; 2003 Nov; 291(1):1-10. PubMed ID: 14597403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
    Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
    Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cooperation of urokinase plasminogen activator and matrix metalloproteinases in NK cell invasion.
    al-Atrash G; Kitson RP; Xue Y; Goldfarb RH
    In Vivo; 2000; 14(5):565-70. PubMed ID: 11125540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.